Comparative Pharmacology
Head-to-head clinical analysis: MINZOYA versus ZOVIA 1 35E 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINZOYA versus ZOVIA 1 35E 21.
MINZOYA vs ZOVIA 1/35E-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Zinc pyrithione is an antimicrobial agent that inhibits fungal growth by disrupting membrane transport and inhibiting mitochondrial function, leading to cell death.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibits ovulation, alters cervical mucus and endometrial lining.
Intravenous infusion of 300 mg over 30 minutes every 4 weeks.
One tablet orally once daily at the same time each day for 21 days, followed by 7 placebo tablets (if included in the pack) or a 7-day pill-free interval. Each tablet contains ethinyl estradiol 0.035 mg and norethindrone 1 mg.
None Documented
None Documented
Terminal elimination half-life of 20-30 hours; at steady state after 5-7 days, half-life reflects accumulation for once-daily dosing.
Norethindrone: 5-12 hours (terminal elimination half-life, approximately 8 hours). Ethinyl estradiol: biphasic with terminal half-life of 10-20 hours (mean 15 hours). Clinical context: Steady state reached in 5-7 days.
Primarily hepatic metabolism with renal excretion of metabolites (50-60% as unchanged drug and conjugates); approximately 30-40% fecal elimination.
Renal (approximately 40% as parent drug and metabolites; 20-40% as metabolites; 15-20% as unchanged drug), fecal (30-50% via bile as metabolites), and less than 2% in breast milk.
Category C
Category C
Oral Contraceptive
Oral Contraceptive